About Inter-alpha-trypsin inhibitor heavy chain H5
Inter-alpha-trypsin inhibitor heavy chain H5 (ITIH5) is a protein
from Homo sapiens identified by UniProt accession
Q86UX2, 942 residues long.
MolForge cross-references it against 0 known binders and
0 disease associations.
Target properties
| Protein name | Inter-alpha-trypsin inhibitor heavy chain H5 |
|---|
| UniProt accession | Q86UX2 |
|---|
| Gene | ITIH5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 942 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86UX2-F1 | alphafold | PREDICTED | 78.24 | — |
Amino-acid sequence (942 residues)
MLLLLGLCLG LSLCVGSQEE AQSWGHSSEQ DGLRVPRQVR LLQRLKTKPL MTEFSVKSTI ISRYAFTTVS CRMLNRASED QDIEFQMQIP AAAFITNFTM LIGDKVYQGE ITEREKKSGD RVKEKRNKTT EENGEKGTEI FRASAVIPSK DKAAFFLSYE ELLQRRLGKY EHSISVRPQQ LSGRLSVDVN ILESAGIASL EVLPLHNSRQ RGSGRGEDDS GPPPSTVINQ NETFANIIFK PTVVQQARIA QNGILGDFII RYDVNREQSI GDIQVLNGYF VHYFAPKDLP PLPKNVVFVL DSSASMVGTK LRQTKDALFT ILHDLRPQDR FSIIGFSNRI KVWKDHLISV TPDSIRDGKV YIHHMSPTGG TDINGALQRA IRLLNKYVAH SGIGDRSVSL IVFLTDGKPT VGETHTLKIL NNTREAARGQ VCIFTIGIGN DVDFRLLEKL SLENCGLTRR VHEEEDAGSQ LIGFYDEIRT PLLSDIRIDY PPSSVVQATK TLFPNYFNGS EIIIAGKLVD RKLDHLHVEV TASNSKKFII LKTDVPVRPQ KAGKDVTGSP RPGGDGEGDT NHIERLWSYL TTKELLSSWL QSDDEPEKER LRQRAQALAV SYRFLTPFTS MKLRGPVPRM DGLEEAHGMS AAMGPEPVVQ SVRGAGTQPG PLLKKPYQPR IKISKTSVDG DPHFVVDFPL SRLTVCFNID GQPGDILRLV SDHRDSGVTV NGELIGAPAP PNGHKKQRTY LRTITILINK PERSYLEITP SRVILDGGDR LVLPCNQSVV VGSWGLEVSV SANANVTVTI QGSIAFVILI HLYKKPAPFQ RHHLGFYIAN SEGLSSNCHG LLGQFLNQDA RLTEDPAGPS QNLTHPLLLQ VGEGPEAVLT VKGHQVPVVW KQRKIYNGEE QIDCWFARNN AAKLIDGEYK DYLAFHPFDT GMTLGQGMSR EL
Explore Inter-alpha-trypsin inhibitor heavy chain H5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets